The Committee for Medicinal Products for Human Use (CHMP) decided that Zavesca’ s benefits are greater than its risks for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease for whom ERT is unsuitable, and of progressive neurological manifestations in adult and paediatric patients with Niemann-Pick type C disease.